REBOOT
Financiado
First in class implants for bone regeneration surgery after a bone ligament or...
First in class implants for bone regeneration surgery after a bone ligament or tendon injury
NORAKER develops first-in-class implants for regenerative orthopaedic surgery to offer full healing to patients suffering from a bone, ligament or tendon injury. With project REBOOT, NORAKER will create the market of bone regenera...
NORAKER develops first-in-class implants for regenerative orthopaedic surgery to offer full healing to patients suffering from a bone, ligament or tendon injury. With project REBOOT, NORAKER will create the market of bone regeneration surgery.
Each year in Europe, 1,6 million people require orthopaedic surgery after a bone, ligament or tendon injury, with many more cases expected as population ages. The current implants (made of metallic or bioresorbable materials) show imperfect healing outcomes, leaving millions of patients with fragile bones and poor quality of life (with 30% of inflammation, 20% of revision surgery and millions suffering from chronic pain and musculoskeletal disorders, MSDs). It weights billions of follow-up costs on the community.
Enter NORAKER’s biocomposite surgical implants, made of bioactive glass – a revolutionary ceramic – mixed with a synthetic polymer, both bioabsorbable. This technology shows disruptive regeneration action: it can recreate up to 100% of the native-like functional bone structure with no inflammation, no abnormal pain, no MSD and a very low re-operation rate (4%).
Today this patented technology is adapted to knee cruciate ligaments regeneration (with a world-first biocomposite screw marketed in 2015).
In a SME Instrument Phase 1 project (2018), NORAKER has validated the feasibility of a new biocomposite formula with broader perspectives of regeneration for tendon, ligament and bone injuries.
The Phase 2 project will do the industrial scale-up of this biocomposite and launch the industrial production of the first range of implants for the bone trauma market. Their adoption will support the transition toward regenerative orthopaedic surgery and break the spiral of pain and MSDs, which too many patients are experiencing these days.
With this disruptive offer, NORAKER will become a scale-up operating worldwide, with a large manufacturing capablity, international sales and turnover multiplied by 15 in five years.
ver más
Duración del proyecto: 48 meses
Fecha Inicio: 2019-10-10
Fecha Fin: 2023-10-31
Fecha Fin: 2023-10-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2023-10-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
NORAKER
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
506.47K€ |
Participante